In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic rhinosinusitis (CRS) nasal spray Xhance for up to $330 million. More: Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to
read moreTwo “concerned shareholders” are calling for an immediate strategic review at Amarin two years after a heated public back-and-forth between Amarin and another activist investor, Sarissa Capital. More: Investor group calls for strategy shift as Amarin shares continue to flounder
read moreGlobal pharma giants AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Pfizer and more are calling for the U.K. government to afford the industry more room for growth by revising a drug cost control program. More: Calling UK 'uninvestable,' pharma
read moreAspen Pharmacare, the largest drugmaker on the African continent, was slammed in a warning letter by the FDA citing sterility issues that could lead to microbial contamination. The write-up follows a September inspection of Aspen’s Gqeberha, South Africa, plant, which
read moreIn an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new awareness campaign for pneumococcal pneumonia vaccination. More: Pfizer enlists Elizabeth Banks for Gen X-focused pneumococcal vaccine push Source:
read more
The company is preparing to submit the results to the FDA this year More: Orca Bio’s T-cell therapy shows promise in haematological malignancies Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals